Lipovka Yulia, Konhilas John P
Department of Physiology, University of Arizona, Sarver Molecular Cardiovascular Research Program, USA.
Cardiovasc Pharm Open Access. 2015 Aug;4(3). doi: 10.4172/2329-6607.1000154. Epub 2015 Aug 31.
The AMP-protein kinase (AMPK) pathway is very versatile as it regulates cellular energetic homeostasis in many different tissue types. An appreciation for the importance of AMPK signalling and regulation in cardiovascular and tumor biology is increasing. Recently, a link has been established between anti-cancer therapy and susceptibility to cardiac disease. It has been shown that some anti-cancer drugs lead to an increased risk of cardiac disease, underlined by de-regulation of AMPK signalling. This review explores the AMPK signalling axis in both cardiac and tumor metabolism. We then examine off-target AMPK inhibition by cancer drugs and how this may translate into increased risk of cardiovascular disease. Finally, we discuss the implication of deregulated AMPK signalling during different stages of cardiac hypertrophy. Better understanding of the molecular pathways behind pathological processes will lead to the development of more effective therapeutics for cancer and cardiovascular diseases.
AMP 蛋白激酶(AMPK)通路具有很强的通用性,因为它能调节多种不同组织类型中的细胞能量稳态。人们越来越认识到 AMPK 信号传导和调节在心血管生物学和肿瘤生物学中的重要性。最近,已在抗癌治疗与心脏病易感性之间建立了联系。研究表明,一些抗癌药物会导致心脏病风险增加,AMPK 信号传导失调突出了这一点。本综述探讨了心脏和肿瘤代谢中的 AMPK 信号轴。然后,我们研究了抗癌药物对 AMPK 的脱靶抑制作用以及这如何转化为心血管疾病风险的增加。最后,我们讨论了心脏肥大不同阶段 AMPK 信号传导失调的影响。更好地理解病理过程背后的分子途径将有助于开发更有效的癌症和心血管疾病治疗方法。